Income Taxes	9 Months Ended
Aug. 01, 2014
Income Taxes	Note 7 – Income Taxes The income tax rates were 20.6% and 11.4% for the first nine months of fiscal 2014 and 2013, respectively. In the first nine months of 2014, the Company recognized approximately $1.4 million of discrete tax benefits principally related to the following items. The first item was approximately $0.9 million of tax benefits due to the release of reserves due to the expiration of applicable statutes of limitations. The second item was a $0.5 million reduction of net deferred income tax liabilities as a result of the enactment of tax laws reducing the U.K. statutory income tax rate. In the first nine months of fiscal 2013, the Company recognized $12.4 million of discrete tax benefits principally related to the following items. The first item was approximately $1.5 million of tax benefits due to the retroactive extension of the U.S. federal research and experimentation credits. The second item was approximately $2.3 million of tax benefits related to the settlement of U.S. and foreign tax examinations. The third item was a $4.3 million tax benefit related to the release of tax reserves due to the expiration of applicable statutes of limitations. The fourth item was a $3.8 million reduction of net deferred income tax liabilities as a result of the enactment of tax laws reducing the U.K. statutory income tax rate. The income tax rate differed from the statutory rate in the first nine months of fiscal 2014 and 2013, as both years benefited from various tax credits and certain foreign interest expense deductions. It is reasonably possible that within the next twelve months approximately $1.6 million of tax benefits that are currently unrecognized could be recognized as a result of settlement of examinations and/or the expiration of applicable statutes of limitations.

Income Taxes

9 Months Ended

Aug. 01, 2014

Note 7 – Income Taxes

The income tax rates were 20.6% and 11.4% for the first nine months of fiscal 2014 and 2013, respectively. In the first nine months of 2014, the Company recognized approximately $1.4 million of discrete tax benefits principally related to the following items. The first item was approximately $0.9 million of tax benefits due to the release of reserves due to the expiration of applicable statutes of limitations. The second item was a $0.5 million reduction of net deferred income tax liabilities as a result of the enactment of tax laws reducing the U.K. statutory income tax rate. In the first nine months of fiscal 2013, the Company recognized $12.4 million of discrete tax benefits principally related to the following items. The first item was approximately $1.5 million of tax benefits due to the retroactive extension of the U.S. federal research and experimentation credits. The second item was approximately $2.3 million of tax benefits related to the settlement of U.S. and foreign tax examinations. The third item was a $4.3 million tax benefit related to the release of tax reserves due to the expiration of applicable statutes of limitations. The fourth item was a $3.8 million reduction of net deferred income tax liabilities as a result of the enactment of tax laws reducing the U.K. statutory income tax rate. The income tax rate differed from the statutory rate in the first nine months of fiscal 2014 and 2013, as both years benefited from various tax credits and certain foreign interest expense deductions.

It is reasonably possible that within the next twelve months approximately $1.6 million of tax benefits that are currently unrecognized could be recognized as a result of settlement of examinations and/or the expiration of applicable statutes of limitations.